Shares of Emcure Pharmaceuticals fell nearly 2% to close at ₹1,258.40 on Thursday after reports emerged that Bain Capital, through BC Investments, sold approximately 45.51 lakh shares, representing about 2.4% of the company’s equity, via a large block deal.
According to reports, the shares changed hands at ₹1,262 per share, amounting to a deal size of about ₹574 crore, slightly higher than the earlier reported estimate of ₹551 crore. The offer price was around a 4% discount to the previous closing price of ₹1,279.80.
The stock traded in a day range of ₹1,250–₹1,282 on the NSE, while the market capitalization stood at about ₹242.6 billion, with a P/E ratio of 35.09 and a 52-week range of ₹889–₹1,580.
This sale marks another round of stake reduction by Bain Capital, which has been gradually paring down its holding in the company since its IPO. Reports also noted that the remaining stake of Bain Capital is subject to a 90-day lock-in, and Kotak Securities acted as the banker for the transaction.
Investors are now keenly watching how the market digests the additional supply of shares and whether the stock stabilizes in the coming sessions.
